Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TAGRISSO AstraZeneca Pty Ltd
Product name
TAGRISSO
Sponsor
Accepted date
Oct-2023
Active ingredients
osimertinib mesilate
Proposed indication
TAGRISSO is indicated in combination for locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations.
Application type
C (new indication)
Publication date
Oct-2023